Cargando…
Largazole Inhibits Ocular Angiogenesis by Modulating the Expression of VEGFR2 and p21
Ocular angiogenic diseases, characterized by abnormal blood vessel formation in the eye, are the leading cause of blindness. Although Anti-VEGF therapy is the first-line treatment in the market, a substantial number of patients are refractory to it or may develop resistance over time. As uncontrolle...
Autores principales: | Qiu, Beiying, Tan, Alison, Tan, Yu Zhi, Chen, Qi-Yin, Luesch, Hendrik, Wang, Xiaomeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401058/ https://www.ncbi.nlm.nih.gov/pubmed/34436310 http://dx.doi.org/10.3390/md19080471 |
Ejemplares similares
-
Largazole Pharmacokinetics in Rats by LC-MS/MS
por: Yu, Mingming, et al.
Publicado: (2014) -
Complement Factor B Mediates Ocular Angiogenesis through Regulating the VEGF Signaling Pathway
por: Murray, Hannah, et al.
Publicado: (2021) -
Largazole and Its Derivatives Selectively Inhibit Ubiquitin Activating Enzyme (E1)
por: Ungermannova, Dana, et al.
Publicado: (2012) -
Unexpected Enhancement of HDACs Inhibition by MeS Substitution at C-2 Position of Fluoro Largazole
por: Zhang, Bingbing, et al.
Publicado: (2020) -
Synthetic Routes and Biological Evaluation of Largazole and Its Analogues as Potent Histone Deacetylase Inhibitors
por: Li, Shang, et al.
Publicado: (2011)